Publicaciones en colaboración con investigadores/as de University Hospital of Zurich (10)

2023

  1. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

2020

  1. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

    Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740

2019

  1. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119

2015

  1. 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer

    Annals of Oncology, Vol. 26, Núm. 8, pp. 1573-1588

2014

  1. 2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1475-1484

  2. 2nd ESMO consensus conference on lung cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1462-1474

  3. Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer

    Annals of Oncology, Vol. 25, Núm. 9, pp. 1681-1690

2013

  1. Strategies for improving outcomes in NSCLC: A look to the future

    Lung Cancer, Vol. 82, Núm. 3, pp. 375-382

2012

  1. Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

    Lung Cancer, Vol. 76, Núm. 3, pp. 269-279

2008

  1. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the international expanded access program

    Journal of Thoracic Oncology, Vol. 3, Núm. 7, pp. 756-763